Eris Lifesciences share news, announcements and annual reports
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,156.40.
2 Nov: open ₹1,160.00, high ₹1,186.90, low ₹1,150.60
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,096 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.75
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 45,47355.9% delivered
Eris Lifesciences share news and announcements
795 announcements, routine notices left out, newest first. Page 13 of 16.
Jul 2019
20 Jul · Board meeting
19 Jul · Analysts
5 Jul · Buyback
5 Jul · Public Announcement - Buyback of Shares
3 Jul · Corporate action
3 Jul · Board meeting
1 Jul · Analysts
Jun 2019
24 Jun · Board meeting
24 Jun · Analysts
15 Jun · Analysts
12 Jun · Analysts
10 Jun · Analysts
5 Jun · Analysts
May 2019
31 May · Analysts
27 May · Analysts
24 May · Analysts
22 May · Analysts
21 May · Results
21 May · Board meeting
14 May · Analysts
14 May · Board meeting
Apr 2019
18 Apr · Analysts
15 Apr · Analysts
12 Apr · Updates
8 Apr · Analysts
5 Apr · Analysts
Mar 2019
27 Mar · Analysts
26 Mar · Analysts
19 Mar · Management
14 Mar · Analysts
5 Mar · Analysts
Feb 2019
25 Feb · Analysts
22 Feb · Analysts
22 Feb · Analysts
21 Feb · Analysts
18 Feb · Disclosure
13 Feb · Analysts
11 Feb · Analysts
Jan 2019
29 Jan · Results
29 Jan · Board meeting
25 Jan · Analysts
21 Jan · Board meeting